Physiological concentrations of insulin induce endothelin-dependent vasoconstriction of skeletal muscle resistance arteries in the presence of tumor necrosis factor-alpha dependence on c-Jun N-terminal kinase

Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):274-80. doi: 10.1161/01.ATV.0000198248.19391.3e. Epub 2005 Dec 1.

Abstract

Objective: Tumor necrosis factor-alpha (TNF-alpha) has been linked to obesity-related insulin resistance and impaired endothelium-dependent vasodilatation, but the mechanisms have not been elucidated. To investigate whether TNF-alpha directly impairs insulin-mediated vasoreactivity in skeletal muscle resistance arteries and the role of c-Jun N-terminal kinase (JNK) in this interference.

Methods and results: Insulin-mediated vasoreactivity of isolated resistance arteries of the rat cremaster muscle to insulin (4 to 3400 microU/mL) was studied in the absence and presence of TNF-alpha (10 ng/mL). Although insulin or TNF-alpha alone did not affect arterial diameter, insulin induced dose-dependent vasoconstriction of cremaster resistance arteries in the presence of TNF-alpha, (-12+/-1% at 272 microU/mL). Blocking endothelin receptors in the absence of TNF-alpha uncovered insulin-mediated vasodilatation (18+/-6% at 272 microU/mL) but not in the presence of TNF-alpha (2+/-2% at 272 microU/mL), showing that TNF-alpha inhibits vasodilator effects of insulin. Using digital imaging microscopy, we discovered that TNF-alpha activates JNK in arterial endothelium, visible as an increase in phosphorylated JNK. Moreover, inhibition of JNK with the cell-permeable peptide inhibitor L-JNKI abolished insulin-mediated vasoconstriction in the presence of TNF-alpha, showing that JNK is required for interaction between TNF-alpha and insulin.

Conclusions: TNF-alpha inhibits vasodilator but not vasoconstrictor effects of insulin in skeletal muscle resistance arteries, resulting in insulin-mediated vasoconstriction in the presence of TNF-alpha. This effect of TNF-alpha is critically dependent on TNF-alpha-mediated activation of JNK.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Arteries / drug effects
  • Arteries / physiology
  • Endothelin-1 / antagonists & inhibitors
  • Endothelin-1 / metabolism
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology
  • Hypoglycemic Agents / pharmacology*
  • Insulin / pharmacology*
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Muscle, Skeletal / blood supply
  • Oligopeptides / pharmacology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha / metabolism*
  • Vascular Resistance
  • Vasoconstriction / drug effects*
  • Vasoconstriction / physiology
  • Vasodilation / drug effects
  • Vasodilation / physiology
  • Vasodilator Agents / pharmacology

Substances

  • Endothelin-1
  • Hypoglycemic Agents
  • Insulin
  • Oligopeptides
  • Tumor Necrosis Factor-alpha
  • Vasodilator Agents
  • PD 142893
  • Proto-Oncogene Proteins c-akt
  • JNK Mitogen-Activated Protein Kinases
  • Acetylcholine